Cafepharma Today

AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Yahoo/AP
Friday, September 5, 2008 - 10:11am
tags:
Yahoo/TheStreet.com
Friday, September 5, 2008 - 9:08am
tags:
Forbes
Friday, September 5, 2008 - 9:07am
tags:
Pharmaceutical Business Review
Friday, September 5, 2008 - 9:04am
tags:
Yahoo/Businessweek
Friday, September 5, 2008 - 9:03am
tags:
Seeking Alpha
Friday, September 5, 2008 - 9:01am
tags:
Businessweek
Friday, September 5, 2008 - 8:59am
tags:
Star Ledger, NJ
Friday, September 5, 2008 - 8:56am
tags:
Pharmaceutical Business Review
Friday, September 5, 2008 - 8:54am
tags:
Yahoo/AP
Friday, September 5, 2008 - 8:53am
tags:
CNBC
Thursday, September 4, 2008 - 5:17pm
tags:
Yahoo/AP
Thursday, September 4, 2008 - 5:16pm
tags:
Yahoo/Real Money/TheStreet.com
Thursday, September 4, 2008 - 2:57pm
tags:
Yahoo/Zacks.com
Thursday, September 4, 2008 - 2:56pm
tags:
CNBC
Thursday, September 4, 2008 - 2:50pm
tags:
Bizjournals.com
Thursday, September 4, 2008 - 2:49pm
tags:
CNBC
Thursday, September 4, 2008 - 2:48pm
tags:
Bloomberg
Thursday, September 4, 2008 - 2:47pm
tags:
Yahoo/Zacks.com
Thursday, September 4, 2008 - 11:15am
tags:
Yahoo/Reuters
Thursday, September 4, 2008 - 11:14am
tags:

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.